Biotechnology
Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
SUZHOU, China and ROCKVILLE, Md., March 11, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical...
2021-03-11 08:35
2843
Non-Invasive Liquid Biopsy to Help Cancer Diagnosis Gets CE Certification
LONDON, March 11, 2021 /PRNewswire/ -- Datar Cancer Genetics, a global leader in non-invasive cancer diagnostics, has received Conformité Européenne (CE) Mark for its innovative TruBlood solution, a new paradigm in cancer detection, diagnosis and management. TruBlood is a blood-based, non-invasi...
2021-03-11 07:00
3007
Viva Biotech Successfully Held 2021 Partnership Summit -- Novel Drug 2021, the Persistence and Transformation of Start-up Founders
SHANGHAI, March 10, 2021 /PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including representatives from global investment institutions, R&D heads from pharmaceutical companies, and business development leader...
2021-03-10 20:18
6813
Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization
SHANGHAI, March 9, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, today announced the completion of overUS$100 million Series B financing. The Series B round was led by Loyal Valley Capital...
2021-03-10 08:00
1906
Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
* ALA-1000 is the first, three-month slow-release Buprenorphine injection. * Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. * ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treat...
2021-03-10 00:00
1511
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study
* Genome and Company expands collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for further clinical combination study of GEN-001 in gastric cancers * Establishment of the efficient "clinical development strategy" for the global immuno-oncology microbiome treatment SEOUL, South Korea,...
2021-03-09 22:00
3310
Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
HONG KONG, March 9, 2021 /PRNewswire/ -- Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico'sChemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietary technology will provide UCB's scientists with the...
2021-03-09 22:00
2354
Novartis receives approval for Kymriah (tisagenlecleucel) by Health Sciences Authority as Singapore's first commercially approved CAR-T therapy
* Kymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy approved inSingapore, is indicated as a one-time treatment manufactured individually for each patient. * Novartis works closely with qualified centres to deliver this treatment for eligible relapsed/refractory (r/r) pediatr...
2021-03-09 20:12
6562
Caris' Precision Oncology Alliance Continues to Grow Internationally as it Welcomes Curie Oncology from Singapore
Curie Oncology expands Caris' collaborative network of oncology institutions focused on research into personalized therapies through precision medicine IRVING, Texas, March 9, 2021 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused o...
2021-03-09 19:30
1721
Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer
ST. LOUIS, March 8, 2021 /PRNewswire/ -- Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced that it has entered into an exclusive license and collaboration agreement withShanghai-based...
2021-03-08 22:00
3321
Origin Agritech Ltd Utilized Gene Editing Technology to Create New Corn Traits
BEIJING, March 8, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, today announced that it has successfully utilized gene editing technology to create new corn traits. Gene editing refers to editing DNA strands by introducing...
2021-03-08 22:00
7103
Changzhou National High-Tech Zone to build 70 new production and service facilities this year
CHANGZHOU, China, March 8, 2021 /PRNewswire/ -- On the morning of February 27th , Changzhou National High-Tech Zone held the groundbreaking ceremony for Phase II of Intersurgical Medical Device (Changzhou) Co., Ltd.'s plant. The ceremony is the first of similar events for zone's 70 planned product...
2021-03-08 17:11
2398
Adlai Nortye Announces Formation of its New Scientific Advisory Board
HANGZHOU, China, March 7, 2021 /PRNewswire/ -- Adlai Nortye, a global clinical-stage biopharmaceutical company, today announced the formation of its new Scientific Advisory Board (SAB) comprised of five internationally renowned experts. The SAB includesRonald M. Evans, PhD (Member of the US Natio...
2021-03-08 09:00
1629
ABclonal Biotechnology Acquires Yurogen Biosystems to Better Serve Diagnostic and Pharmaceutical Researchers Worldwide
BOSTON, March 5, 2021 /PRNewswire/ -- ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMabTM platform, to better serve resea...
2021-03-05 20:00
2832
WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration
SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Wellmarker Bio(www.wmbio.co
2021-03-03 22:00
1725
Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility
WUXI, China, March 3, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the European Medicines Agency (EMA) has completed a remote Pre-Approval Inspection (PAI) on its drug substance facility ...
2021-03-03 18:23
2033
Biotheus Announces the Closing of a New Round of Financing co-led by General Atlantic and IDG Capital
ZHUHAI, China, March 2, 2021 /PRNewswire/ -- Biotheus has announced the successful completion of a fourth round of financing, co-led by General Atlantic, a leading global growth equity investor, and IDG Capital, a global leading investment firm. Other new investors include Kunlun Capital, CPE, an...
2021-03-03 11:37
1572
CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project
SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which ta...
2021-03-03 11:12
1435
Seegene's Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants
* Seegene's new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 minutes * Seegene's proprietary high multiplex technology enables detection of 10 different targets * S. Korean firm to research additional versions of variant diagnostic tests SEOUL, South Korea,...
2021-03-03 09:20
1687
AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy
SEATTLE, March 3, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence inMilan, to increase capacities and implement viral vector su...
2021-03-03 08:00
3057
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6217
